Initiating Drug Therapy in Multiple Sclerosis Patients: Effect on Healthcare Costs
April 06, 2010
Multiple sclerosis (MS) is a disease of inflammatory
demyelination of axons of the central nervous
system that results in episodes of transient neurologic
deficits, progressing to permanent neurologic deterioration
over time.1 The cause of MS remains unclear, but it is
thought to involve both genetic susceptibility and environmental
triggers, possibly viral, which result in self-sustaining
autoimmune dysfunction.